WO2002013826A9 - Anti-cancer composition composed of anti-cancer and anti-malarial drugs - Google Patents
Anti-cancer composition composed of anti-cancer and anti-malarial drugsInfo
- Publication number
- WO2002013826A9 WO2002013826A9 PCT/KR2001/001314 KR0101314W WO0213826A9 WO 2002013826 A9 WO2002013826 A9 WO 2002013826A9 KR 0101314 W KR0101314 W KR 0101314W WO 0213826 A9 WO0213826 A9 WO 0213826A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drugs
- anticancer
- drug
- cancer
- antimalarial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001275821A AU2001275821A1 (en) | 2000-08-02 | 2001-08-02 | Anti-cancer composition composed of anti-cancer and anti-malarial drugs |
EP01953364A EP1313475A4 (en) | 2000-08-02 | 2001-08-02 | Anti-cancer composition composed of anti-cancer and anti-malarial drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR2000/44851 | 2000-08-02 | ||
KR10-2000-0044851A KR100390332B1 (en) | 2000-08-02 | 2000-08-02 | anti-cancer composition composed of anti-cancer and anti-malarial drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002013826A1 WO2002013826A1 (en) | 2002-02-21 |
WO2002013826A9 true WO2002013826A9 (en) | 2003-11-13 |
Family
ID=19681440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2001/001314 WO2002013826A1 (en) | 2000-08-02 | 2001-08-02 | Anti-cancer composition composed of anti-cancer and anti-malarial drugs |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1313475A4 (en) |
KR (1) | KR100390332B1 (en) |
AU (1) | AU2001275821A1 (en) |
WO (1) | WO2002013826A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7108992B2 (en) | 2002-11-27 | 2006-09-19 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
US6916627B2 (en) | 2002-11-27 | 2005-07-12 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
AU2012201742B2 (en) * | 2005-01-19 | 2015-05-14 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
WO2008038291A1 (en) * | 2006-09-27 | 2008-04-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy |
KR101067443B1 (en) * | 2009-06-23 | 2011-09-27 | 여오영 | Local injection composition comprising hydroxychloroquine for treatment of hemorrhoids |
KR101208587B1 (en) | 2009-06-24 | 2012-12-06 | 여오영 | Anticancer composition for local injection comprising hydroxychloroquine |
KR101068202B1 (en) * | 2009-10-27 | 2011-09-28 | 조재용 | Anti-cancer agent composition for stomach cancer comprising vorinostat |
TWI482621B (en) | 2009-12-23 | 2015-05-01 | Sigma Tau Ind Farmaceuti | Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents |
WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
KR101769666B1 (en) | 2015-04-13 | 2017-08-21 | 영남대학교 산학협력단 | Anti-cancer pharmaceutical composition comprising doxorubicin and irinotecan and manufacturing method thereof |
KR101698003B1 (en) | 2016-06-20 | 2017-01-19 | 여오영 | Injectable composition for topical administration for cancer treatment that comprising a quinine salt suspension |
FR3076711B1 (en) * | 2018-01-15 | 2020-10-30 | Inoviem Scient | COMPOSITION INCLUDING HYDROXYCHLOROQUINE AND THERAPEUTIC USE |
EP3793544B1 (en) * | 2018-06-19 | 2023-09-20 | Armaceutica, Inc | Bifunctional compositions for the treatment of cancer |
WO2021105761A1 (en) * | 2019-11-29 | 2021-06-03 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Compositions and their uses for treating cancers |
-
2000
- 2000-08-02 KR KR10-2000-0044851A patent/KR100390332B1/en not_active IP Right Cessation
-
2001
- 2001-08-02 EP EP01953364A patent/EP1313475A4/en not_active Ceased
- 2001-08-02 WO PCT/KR2001/001314 patent/WO2002013826A1/en active Application Filing
- 2001-08-02 AU AU2001275821A patent/AU2001275821A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002013826A1 (en) | 2002-02-21 |
KR100390332B1 (en) | 2003-07-07 |
AU2001275821A1 (en) | 2002-02-25 |
EP1313475A4 (en) | 2004-08-18 |
KR20020011528A (en) | 2002-02-09 |
EP1313475A1 (en) | 2003-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6537984B2 (en) | Uses of diterpenoid triepoxides as an anti-proliferative agent | |
AU2005259002B2 (en) | Treatment of cancer | |
Khalife et al. | Thymoquinone from Nigella sativa seeds promotes the antitumor activity of noncytotoxic doses of topotecan in human colorectal cancer cells in vitro | |
Lian et al. | Genistein‐induced G2‐M arrest, p21WAF1 upregulation, and apoptosis in a non‐small‐cell lung cancer cell line | |
EP1274445B1 (en) | Use of steroidal alkaloids to reverse multidrug resistance | |
KR0171893B1 (en) | Compounds for the reversal of multidrug resistance of cancer cells against cytotoxic drugs and pharmaceutical compositions containing them | |
WO2002013826A9 (en) | Anti-cancer composition composed of anti-cancer and anti-malarial drugs | |
US5541232A (en) | Treatment of multidrug resistant diseases | |
Sugiyama et al. | Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma | |
Shi et al. | Reversal effect of tyroservatide (YSV) tripeptide on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU | |
AU2005211937B2 (en) | Methods for treating resistant or refractory tumors | |
EP1289513B1 (en) | Use of aloe-emodin in the treatment of neuroectodermal tumors | |
US20240042040A1 (en) | Cisplatin analogue with potent anti-cancer effects and synthesis thereof | |
CN112294829A (en) | Application of salidroside in preparation of medicine for treating or preventing cancer | |
권혜정 | Targeting XIAP in mucoepidermoid carcinoma of salivary gland: A novel therapeutic strategy of nitidine chloride | |
Park et al. | Compound 3K, a specific pyruvate kinase M2 inhibitor, induces autophagic cell death through the disruption of the glycolytic pathway in ovarian cancer cells | |
CN111689870A (en) | Honokiol-chlorambucil co-prodrug with lymphocyte leukemia resisting effect and preparation method and application thereof | |
NZ552508A (en) | Treatment of cancer with pharmaceutical agents together with anti-Hsp 90 antibodies | |
Engi | Perspectives in cancer chemotherapy, in vitro and in vivo experiments | |
Gerrard | Modulation of P-glycoprotein by Zosuquidar Trihydrochloride | |
Doğan | A novel chemotherapeutic drug combination for prostate cancer | |
Alhosin et al. | Thymoquinone, is a novel selective microtubule-targeting drug, by inducing the degradation of α and β tubulin in human leukaemia and human astrocytoma cells but not in normal human fibroblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001953364 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001953364 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
COP | Corrected version of pamphlet |
Free format text: INTERNATIONAL SEARCH REPORT ADDED (1 PAGE) |
|
NENP | Non-entry into the national phase |
Ref country code: JP |